UOC
UBS O'Connor Portfolio holdings
AUM
$1.93B
1-Year Return
38.75%
This Quarter Return
+3.8%
1 Year Return
+38.75%
3 Year Return
+182.42%
5 Year Return
+480.25%
10 Year Return
+1,573.29%
AUM
$3.77B
AUM Growth
-$242M
(-6%)
Cap. Flow
-$294M
Cap. Flow
% of AUM
-7.81%
Top 10 Holdings %
Top 10 Hldgs %
58.56%
Holding
566
New
99
Increased
122
Reduced
58
Closed
164
Top Buys
Top Sells
| 1 |
CTLT
CATALENT, INC.
CTLT
|
$234M |
| 2 |
MRO
Marathon Oil Corporation
MRO
|
$222M |
| 3 |
SRCL
Stericycle Inc
SRCL
|
$172M |
| 4 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$150M |
| 5 |
PRFT
Perficient Inc
PRFT
|
$79.6M |
Sector Composition
| 1 | Technology | 30.66% |
| 2 | Energy | 16.79% |
| 3 | Financials | 8.26% |
| 4 | Consumer Staples | 8.25% |
| 5 | Materials | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Xencor
XNCR
$610M
| $897K | 0.02% |
39,040
+7,040
| +22% | +$162K |
|
227
enVVeno Medical
NVNO
$14.9M
| $894K | 0.02% |
296,031
| – | – |
|
|
SLN
228
Silence Therapeutics
SLN
$269M
| $887K | 0.02% |
128,990
+43,289
| +51% | +$298K |
|
229
Ovid Therapeutics
OVID
$87.5M
| $881K | 0.02% |
943,416
+315,126
| +50% | +$294K |
|
230
Viridian Therapeutics
VRDN
$1.53B
| $855K | 0.02% |
+44,600
| New | +$855K |
|
231
Strategy Inc Common Stock Class A
MSTR
$95.2B
| $851K | 0.02% |
+2,937
| New | +$851K |
|
232
UWM Holdings
UWMC
$1.38B
| $839K | 0.02% |
+143,000
| New | +$839K |
|
233
VYNE Therapeutics
VYNE
$7.62M
| $823K | 0.02% |
+245,800
| New | +$823K |
|
234
On Holding
ONON
$14.9B
| $822K | 0.02% |
+15,000
| New | +$822K |
|
235
Zoom
ZM
$25B
| $816K | 0.02% |
+10,000
| New | +$816K |
|
236
Keros Therapeutics
KROS
$633M
| $806K | 0.02% |
50,897
+26,145
| +106% | +$414K |
|
237
Magnite
MGNI
$3.54B
| $796K | 0.02% |
+50,000
| New | +$796K |
|
238
Terns Pharmaceuticals
TERN
$632M
| $777K | 0.02% |
140,300
+92,300
| +192% | +$511K |
|
239
Neurogene
NGNE
$285M
| $748K | 0.02% |
32,734
+23,907
| +271% | +$547K |
|
240
Boston Scientific
BSX
$159B
| $744K | 0.02% |
8,334
+1,507
| +22% | +$135K |
|
241
Larimar Therapeutics
LRMR
$337M
| $730K | 0.02% |
188,543
-14,240
| -7% | -$55.1K |
|
242
Edwards Lifesciences
EW
$47.5B
| $723K | 0.02% |
9,760
+2,760
| +39% | +$204K |
|
|
SPKL
243
Spark I Acquisition Corp
SPKL
$94.8M
| $711K | 0.02% |
66,832
| – | – |
|
|
CNTB
244
Connect Biopharma Holdings Limited Ordinary Shares
CNTB
$97.5M
| $705K | 0.02% |
510,701
| – | – |
|
245
Cullinan Oncology
CGEM
$413M
| $683K | 0.02% |
56,095
+10,120
| +22% | +$123K |
|
|
SLRN
246
DELISTED
ACELYRIN
SLRN
| $665K | 0.02% |
211,938
+48,214
| +29% | +$151K |
|
247
Airbnb
ABNB
$75.8B
| $657K | 0.02% |
+5,000
| New | +$657K |
|
248
Day One Biopharmaceuticals
DAWN
$773M
| $634K | 0.02% |
+50,020
| New | +$634K |
|
249
Acrivon Therapeutics
ACRV
$41.8M
| $619K | 0.02% |
102,784
+23,535
| +30% | +$142K |
|
250
Merus
MRUS
$5.1B
| $611K | 0.02% |
14,540
+4,618
| +47% | +$194K |
|